|
Pacira reports Phase 3 study results of Exparel
Pharmaceutical Business Review Pacira Pharmaceuticals' Exparel (bupivacaine liposome injectable suspension), a non-opioid local analgesic, for administration into the surgical site to produce postsurgical analgesia has reported pain reduction in a pivotal Phase 3 trial. ... Pacira Pharmaceuticals, Inc. Announces Results from EXPAREL™ Pivotal Trial ...PR Newswire (press release) Pacira Pharmaceuticals Announces Results from EXPAREL Pivotal Trial Published ...Benzinga |
Read the full story:
Pacira reports Phase 3 study results of Exparel - Pharmaceutical Business Review
You must log in to post a comment.